Kamrul Hassan

Comparative Study of Serum Bilirubin Level between Term and Preterm Babies in Mymensingh Medical College Hospital

Neonatal jaundice is observed during 1st week of life in approximately 60% of term infants and 80% of preterm infants. All jaundiced newborns are at potential risk for developing severe hyperbilirubinemia if there is uncontrolled or managed inappropriately. The objective of this study is to compare serum bilirubin level of term and preterm babies. A cross-sectional study was conducted with total of 100 newborns babies who were admitted into neonatal unit, babies from obstetric department and who came for checkup and follow up in neonatal unit of Mymensingh Medical College Hospital, Mymensingh during the period August 2006 to January 2007. In this study, mean gestational age of term babies was 38.9±1.22 weeks and of preterm babies was 34.64±1.05 weeks. Mean bilirubin levels observed in term babies 6.68 and 5.72 mg/dl on day 3 and day 5 respectively. In preterm babies, the mean bilirubin levels were 7.16 and 9.09 mg/dl on day 3 and day 5 respectively. Statistically significant differences were observed in bilirubin level on day 5 in both term and preterm groups (p<0.05). Incidence of jaundice among term babies was 64.0% and among preterm babies was 84.0%. Jaundice developed significantly more among the preterm babies than the term babies (p<0.05). From this study, it can be concluded that in premature infants, the rate of rise in serum bilirubin tends to be the same or a little slower and mean serum bilirubin level was higher than that of term babies. Faridpur Med. Coll. J. Jan 2017;12(1): 5-8

Use of Propranolol for the management of haemangioma in children: Our experience

Hemangioma is one of the most common benign tumors of infancy and occurs in approximately 5-10% of infants. The treatment options for problematic haemangioma are intralesional and systemic steroids, chemotherapeutic agents including vincristine and interferon-alpha, laser therapy or surgical intervention. In this case series effectiveness of propranolon was observed on haemangioma. This study was conducted in the Department of Pediatric Surgery, Faridpur Medical College Hospital, Faridpur and Shahid Ziaur Rahman Medical College, Bogra. This study period was from January 2013 to December 2015. A total of 38 patients of haemangioma were admitted in Pediatric Surgery ward in FMCH and 26 patients in SZRMCH. These 54 patients were counseled about the study in detail. First dose of propranolol was given at a dose of 3 mg/kg/day in three divided doses. Pulse and blood pressure were recorded during initial 3 hours. Patients were then advised to continue with this treatment at home, with monthly follow-up. Total number of patients were 54. Of them 11 were male and 43 were female, giving a male: female ratio of 1:4. 60 % of the patients (32) were in <6 months. After 1 month, sign of regression was marked in all cases. Complete regression was seen in 6 patients (11.1 %) during second follow-up after 3 months of treatment. Only 4 patient required 9 months to reach the complete recovery. This case series contributes to the growing evidence that oral propranolol is efficacious and safe, with a careful dosing and monitoring. We hope a national guidelines will be developed in time for use of propranolol to treat the haemangioma. Faridpur Med. Coll. J. Jul 2017;12(2): 71-74